Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052)

BACKGROUND: Poly (adenosine diphosphate)-ribose polymerase (PARP) inhibitors for tumors with homologous recombination deficiency (HRD), including pathogenic mutations in BRCA1/2, have been developed. Genomic analysis revealed that about 20% of uterine leiomyosarcoma (uLMS) have HRD, including 7.5%–1...

Descripción completa

Detalles Bibliográficos
Autores principales: Asano, Hiroshi, Oda, Katsutoshi, Yoshihara, Kosuke, Ito, Yoichi M, Matsumura, Noriomi, Shimada, Muneaki, Watari, Hidemichi, Enomoto, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 2022
Materias:
Clinical Trial Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250862/
https://www.ncbi.nlm.nih.gov/pubmed/35557035
http://dx.doi.org/10.3802/jgo.2022.33.e55

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250862/
https://www.ncbi.nlm.nih.gov/pubmed/35557035
http://dx.doi.org/10.3802/jgo.2022.33.e55

Ejemplares similares